BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31074035)

  • 1. Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma.
    Shen XY; Liu XP; Song CK; Wang YJ; Li S; Hu WD
    J Cell Physiol; 2019 Dec; 234(12):22311-22320. PubMed ID: 31074035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
    BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals.
    Li S; Yang R; Sun X; Miao S; Lu T; Wang Y; Wo Y; Jiao W
    Gene; 2018 Dec; 679():398-404. PubMed ID: 30240883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
    Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
    J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eight-gene signature predicts recurrence in lung adenocarcinoma.
    Zhang Y; Fan Q; Guo Y; Zhu K
    Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
    Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
    J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering N
    Zhu J; Wang M; Hu D
    Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
    Xu Z; Chen C
    Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma.
    Liu XX; Yang YE; Liu X; Zhang MY; Li R; Yin YH; Qu YQ
    J Transl Med; 2019 Feb; 17(1):50. PubMed ID: 30777071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.